German
|
English
|
French
Apotheken
|
Doctor
|
Drugs
|
Hospital
|
Interactions
|
MiGeL
|
Registration owner
|
Services
Home
<
List for "D11AH" (46)
–
Sort according to Concentration, Size and Price
Price comparison
Price comparison and Component
Brand name
Component
Registration owner
Indication
Interaction
Unwanted Effect
Swissmedic-# (5-digit)
Pharmacode
Product
Package Size
EFP
CP
SB
DC
Composition
Registr. Holder
Category
Agents for Dermatitis, Excluding Corticosteroids (D11AH) 2 products
WHO-DDD
L
IP
CI
Alitretinoin Leman 10 mg
30
165.00
199.65
10 %
Soft capsules: Alitretinoinum 10 mg
Leman SKL SA
A / SL / SG
FB
G
L
IP
CI
Alitretinoin Leman 30 mg
30
165.00
199.65
10 %
Soft capsules: Alitretinoinum 30 mg
Leman SKL SA
A / SL / SG
FB
G
Tacrolimus (D11AH01) 15 products
WHO-DDD
DrugBank.ca
L
IP
CI
Protopic 0,03 %
30 g
24.60
43.15
10 %
Ointment: Tacrolimusum
LEO Pharmaceutical
Products Sarath Ltd.
B / SL
FB
G
L
IP
CI
Protopic 0,03 %
60 g
43.26
63.45
10 %
Ointment: Tacrolimusum
LEO Pharmaceutical
Products Sarath Ltd.
B / SL
FB
G
L
IP
CI
Protopic 0,1 %
30 g
27.29
46.10
10 %
Ointment: Tacrolimusum 1 mg
LEO Pharmaceutical
Products Sarath Ltd.
B / SL
FB
G
L
IP
CI
Protopic 0,1 %
60 g
47.98
68.60
10 %
Ointment: Tacrolimusum 1 mg
LEO Pharmaceutical
Products Sarath Ltd.
B / SL
FB
G
L
IP
CI
Tacrocutan 1 mg/g
30 g
21.74
40.05
10 %
Ointment: 2 Active Agents
Dermapharm AG
B / SL
FB
G
L
IP
CI
Tacrocutan 1 mg/g
60 g
38.26
58.05
10 %
Ointment: 2 Active Agents
Dermapharm AG
B / SL
FB
G
L
IP
CI
Tacrocutan 0,03%
30 g
19.60
37.75
10 %
Ointment: Tacrolimusum
Dermapharm AG
B / SL
FB
G
L
IP
CI
Tacrocutan 0,03%
60 g
34.47
53.90
10 %
Ointment: Tacrolimusum
Dermapharm AG
B / SL
FB
G
IP
CI
Takrozem 1 mg/g
10 g
k.A.
Ointment: Tacrolimusum 1 mg
Pierre Fabre Pharma SA
B
FB
G
IP
CI
Takrozem 1 mg/g
30 g
23.25
41.70
k.A.
Ointment: Tacrolimusum 1 mg
Pierre Fabre Pharma SA
B
FB
G
IP
CI
Takrozem 1 mg/g
60 g
40.92
60.90
k.A.
Ointment: Tacrolimusum 1 mg
Pierre Fabre Pharma SA
B
FB
G
IP
CI
Tacrocutan 1 mg/g
10 g
k.A.
Ointment: 2 Active Agents
Dermapharm AG
B
FB
G
IP
CI
Takrozem 0,3 mg/g
10 g
k.A.
Ointment: Tacrolimusum
Pierre Fabre Pharma SA
B
FB
G
IP
CI
Takrozem 0,3 mg/g
30 g
k.A.
Ointment: Tacrolimusum
Pierre Fabre Pharma SA
B
FB
G
IP
CI
Takrozem 0,3 mg/g
60 g
k.A.
Ointment: Tacrolimusum
Pierre Fabre Pharma SA
B
FB
G
Pimecrolimus (D11AH02) 2 products
WHO-DDD
DrugBank.ca
L
SIP
IP
CI
Elidel 1 %
30 g
25.57
44.20
10 %
Cream: Pimecrolimusum 10 mg
Viatris Pharma GmbH
B / SL
FB
G
L
SIP
IP
CI
Elidel 1 %
60 g
44.84
65.20
10 %
Cream: Pimecrolimusum 10 mg
Viatris Pharma GmbH
B / SL
FB
G
Alitretinoin (D11AH04) 4 products
WHO-DDD
DrugBank.ca
L
IP
CI
Toctino 10 mg
30 Capsule(s)
181.45
216.50
10 %
Soft capsules: Alitretinoinum 10 mg
GlaxoSmithKline AG
A / SL / SO
FB
G
L
IP
CI
Toctino 30 mg
30 Capsule(s)
181.45
216.50
10 %
Soft capsules: Alitretinoinum 30 mg
GlaxoSmithKline AG
A / SL / SO
FB
G
L
IP
CI
Alitrecutan 10 mg
30
180.00
215.05
10 %
Soft capsules: Alitretinoinum 10 mg
Dermapharm AG
A / SL / SG
FB
G
L
IP
CI
Alitrecutan 30 mg
30
180.00
215.05
10 %
Soft capsules: Alitretinoinum 30 mg
Dermapharm AG
A / SL / SG
FB
G
Dupilumab (D11AH05) 6 products
WHO-DDD
L
IP
CI
Dupixent 300 mg/2 ml
2
1004.52
1108.90
10 %
solution injectable en seringue préremplie avec système de sécurité: Dupilumabum 300mg / 2ml
Sanofi-Aventis
(Suisse) SA
B / SL
FB
G
L
IP
CI
Dupixent 200 mg/1.14 ml
2
1004.52
1108.90
10 %
solution injectable en seringue préremplie avec système de sécurité: Dupilumabum 200mg / 1.14ml
Sanofi-Aventis
(Suisse) SA
B / SL
FB
G
L
IP
CI
Dupixent 300 mg/ 2 ml
2 x 2 ml
1004.52
1108.90
10 %
solution injectable en stylo pré-rempli: Dupilumabum 300mg / 2ml
Sanofi-Aventis
(Suisse) SA
B / SL
FB
G
L
IP
CI
Dupixent 200 mg/ 1.14 ml
2 x 1.14 ml
1004.52
1108.90
10 %
solution injectable en stylo pré-rempli: Dupilumabum 200mg / 1.14ml
Sanofi-Aventis
(Suisse) SA
B / SL
FB
G
IP
CI
Dupixent 300 mg/ 2 ml
2 x 2 ml
1065.68
1175.40
k.A.
solution injectable en stylo pré-rempli: Dupilumabum 300mg / 2ml
Sanofi-Aventis
(Suisse) SA
B
FB
G
IP
CI
Dupixent 200 mg/ 1.14 ml
2 x 1.14 ml
1065.68
1175.40
k.A.
solution injectable en stylo pré-rempli: Dupilumabum 200mg / 1.14ml
Sanofi-Aventis
(Suisse) SA
B
FB
G
Tralokinumab (D11AH07) 2 products
WHO-DDD
L
IP
CI
Adtralza 150mg/ml
4
951.65
1051.40
10 %
Injection solution in prefilled syringe: Tralokinumabum 150 mg/ml
LEO Pharmaceutical
Products Sarath Ltd.
B / SL
FB
G
L
IP
CI
Adtralza 300 mg/2 mL
2 x 2 ml
951.65
1051.40
10 %
Injektionslösung im Fertigpen: Tralokinumabum 300mg / 2ml
LEO Pharmaceutical
Products Sarath Ltd.
B / SL
FB
G
Abrocitinib (D11AH08) 6 products
WHO-DDD
L
IP
CI
Cibinqo 50 mg
28
853.98
945.15
10 %
Coated tablets: Abrocitinibum 50 mg
Pfizer AG
B / SL
FB
G
L
IP
CI
Cibinqo 100 mg
28
853.98
945.15
10 %
Coated tablets: Abrocitinibum 100 mg
Pfizer AG
B / SL
FB
G
IP
CI
Cibinqo 50 mg
14
k.A.
Coated tablets: Abrocitinibum 50 mg
Pfizer AG
B
FB
G
IP
CI
Cibinqo 50 mg
91
k.A.
Coated tablets: Abrocitinibum 50 mg
Pfizer AG
B
FB
G
IP
CI
Cibinqo 100 mg
14
k.A.
Coated tablets: Abrocitinibum 100 mg
Pfizer AG
B
FB
G
IP
CI
Cibinqo 100 mg
91
k.A.
Coated tablets: Abrocitinibum 100 mg
Pfizer AG
B
FB
G
Ruxolitinib (D11AH09) 2 products
WHO-DDD
L
IP
CI
Opzelura 15 mg/g
100 g
691.19
768.15
10 %
Cream: Ruxolitinibum 15 mg
Incyte Biosciences
International Sàrl
B / SL
FB
G
L
IP
CI
Opzelura 15 mg/g
100 g
691.19
768.15
10 %
Cream: Ruxolitinibum 15 mg
Incyte Biosciences
International Sàrl
B / SL
FB
G
Lebrikizumab (D11AH10) 4 products
WHO-DDD
L
IP
CI
Ebglyss 250 mg/2 ml
2
1726.04
1893.60
10 %
Injection solution in prefilled syringe: Lebrikizumabum 250mg / 2ml
Almirall AG
B / SL
FB
G
L
IP
CI
Ebglyss 250 mg/2 ml
2 x 2 ml
1726.04
1893.60
10 %
Injektionslösung in Fertigpen: Lebrikizumabum 250mg / 2ml
Almirall AG
B / SL
FB
G
IP
CI
Ebglyss 250 mg/2 ml
k.A.
Injection solution in prefilled syringe: Lebrikizumabum 250mg / 2ml
Almirall AG
B
FB
G
IP
CI
Ebglyss 250 mg/2 ml
2 ml
k.A.
Injektionslösung in Fertigpen: Lebrikizumabum 250mg / 2ml
Almirall AG
B
FB
G
Delgocitinib (D11AH11) 1 products
WHO-DDD
L
IP
CI
Anzupgo 20 mg/g
60 g
570.82
637.20
10 %
Cream: Delgocitinibum 20 mg
LEO Pharmaceutical
Products Sarath Ltd.
B / SL
FB
G
Nemolizumab (D11AH12) 2 products
WHO-DDD
L
IP
CI
Nemluvio 30 mg
30 mg
1905.50
2088.75
10 %
Pulver und Lösungsmittel für Injektionslösung im Fertigpen: Nemolizumabum 30 mg
Galderma SA
B / SL / SG
FB
G
IP
CI
Nemluvio 30 mg
2 x 30 mg
k.A.
Pulver und Lösungsmittel für Injektionslösung im Fertigpen: Nemolizumabum 30 mg
Galderma SA
B
FB
G
show caption
Red = Original
CM
= Co-Marketing
EFP = Ex-Factory-Price, exkl. VAT CHF
Green = Generic Drug
V/S
= vaccine/blood product
CP = Consumer Price, inkl. VAT CHF
Black = not classified
A
= Anesthetic
PR = Price request
Gray background = Pending Permission Extension
SIP
= Short Information for Professionals
SB = Selbstbehalt
H
= Homeopathics
IP
= Information for Professionals
DC = Daily Cost
A
= Anthroposophics
CI
= Consumer Information
SL = Official reimbursement list of Switzerland.
Ph
= Phytotherapeutics
L
= Limitations
SO = Original according to SL
Cas Reg.Nr. = CAS Registry
G
= Google Search by Product Name
SG = Generic according to SL
P
= Import parallel
FB
= Drugs Feedback
LPPA = Liste des produits pharmaceutiques pour application spéciale
Legal Disclaimer
ATC-Browser
|
Drugs A-Z
|
Recent Registrations
2026
©ywesee GmbH
Settings
|
Help
|
Login
|
Contact
|
Home
